We evaluated the efficacy and safety of the investigational long-acting injectable antipsychotic agent paliperidone palmitate (PP) in the treatment of schizophrenia. Patients were randomized to receive gluteal injections of placebo or PP (50 or 100 mg eq., fixed doses), without oral supplementation, on days 1, 8, and 36 (9-wk, double-blind phase) in this phase 2b study. Patients (n=197, intent-to-treat analysis set) were 62 % men, mean (S.D.) age 39 (10) yr, with a baseline mean (S.D.) Positive and Negative Syndrome Scale (PANSS) total score of 87.0 (12.5). Mean (S.D.) PANSS total scores showed significant improvement at endpoint (primary measure) for both the PP 50 mg eq. [x5.2 (21.5)] and PP 100 mg eq. [x7.8 (19.4)] groups, vs. placebo [6.2 (18.3)] (pf0.001, each dose vs. placebo). This improvement was detected by day 8 and maintained to endpoint (pf0.011) for both doses. In the safety analysis set (n=247), fewer PP-treated patients (2 %) discontinued for treatment-emergent adverse events vs. placebo-treated (10 %). Rates of treatment-emergent extrapyramidal syndrome-related adverse events were comparable between active treatment and placebo, with the exception of parkinsonism-related disorders (50 mg eq. 5 %, 100 mg eq. 8 %, placebo 1 %). Results of other safety measures suggest PP to be generally well-tolerated. Throughout the study, investigators rated injection-site pain as absent (56-71 %), mild (24-39 %), moderate (2-12 %), or severe (0-2 %). PP (50 and 100 mg eq. doses) administered as a gluteal intramuscular injection was efficacious and generally tolerated in these patients with acute symptomatic schizophrenia.
Introduction
Schizophrenia is a chronic disease, associated with ongoing functional impairment and frequent recurrence of acute psychotic symptoms (Andreasen, 1995) . The prognosis and outcomes worsen with each successive relapse (Johnson et al. 1983 ; Kane, 2007 ; Wyatt, 1991) and the chance of relapse increases with poor treatment adherence, a frequent problem among patients diagnosed with schizophrenia who are prescribed oral medications (Robinson et al. 1999) .
Long-acting injectable antipsychotics offer the opportunity for enhanced patient treatment adherence and can simplify the medication regimen for patients and caregivers (Kane, 2003 ; Keith & Kane, 2003 ; Nasrallah, 2007) . Injectable formulations release medication into the plasma on a continuous basis over prolonged periods of time, diminishing the problems typically associated with missed and inconsistent oral dosing (Keith & Kane, 2003) . The use of injectable long-acting medications also allows the clinician to know if a dose is missed and the long half-life of these agents allows time for rescheduling of an appointment for the patient to receive the missed treatment. Finally, if a recurrence of symptoms does occur, the clinician is in a much better position to eliminate non-adherence as a possible cause (Nasrallah, 2007) .
Paliperidone palmitate (PP), an investigational atypical antipsychotic, is the palmitate ester and injectable formulation of paliperidone. As an oral, extended-release formulation, paliperidone is approved in the USA (INVEGA TM ; Janssen, LP), European Union (INVEGA TM ; Janssen-Cilag) and many other countries for both the acute and maintenance treatment of schizophrenia (Davidson et al. 2007 ; Kane et al. 2007 ; Kramer et al. 2007 ; Marder et al. 2007) .
PP, an aqueous nanosuspension, was designed to provide sustained plasma concentrations of the pharmacologically active fraction, paliperidone : this long-acting injectable formulation permits oncemonthly administration in patients. Following delivery into the muscle tissue, the undissolved PP particles form an agglomerate at the injection site, dissolve slowly due to low water solubility, and are then hydrolysed by esterases into paliperidone and palmitic acid. After single gluteal injections of PP 25-150 mg eq., plasma paliperidone concentrations increased slowly, reached C max y2-3 wk after dosing, and declined with a mean t 1/2 of 20-50 d. Based on early trial results, initiation of therapy with two injections, administered 1 wk apart, is considered most appropriate to rapidly achieve therapeutic plasma levels, steady-state, and onset of efficacy, without the need for oral supplementation (Samtani, 2009) . This is an initial phase 2b study designed to evaluate the efficacy and safety of PP, compared to placebo, in patients suffering from schizophrenia.
Method

Patients
Men and women, aged 18-65 yr, were enrolled provided they (1) had a diagnosis of schizophrenia according to DSM-IV criteria for at least 1 yr, (2) had a Positive and Negative Syndrome Scale (PANSS) total score of 70-120 (moderate to severe symptomatology ; Leucht et al. 2005) , inclusive, at screening, and 60-120 inclusive, on day 1 before the start of double-blind study drug, and (3) had a body mass index (BMI) range of 15-35 kg/m 2 . Patients were required to be physically healthy, to be capable of performing study requirements (e.g. evaluation of injection site) and to have agreed to hospitalization for a minimum of 14 d.
Patients were excluded if they had a DSM-IV Axis I diagnosis other than schizophrenia, including a DSM-IV Axis I diagnosis of substance dependence (except nicotine or caffeine) within 3 months prior to screening ; were considered at significant risk for suicidal or aggressive behaviour ; or had a previous lack (within 12 months) of response to two adequate trials of antipsychotic treatment (defined as a minimum of 4-wk treatment at a therapeutic dose). In addition, patients were excluded for : medical conditions that could potentially alter the absorption, metabolism, or excretion of the study medication ; relevant history of significant or unstable medical illness (other than schizophrenia) ; known allergic reactions to risperidone or paliperidone ; use of a depot antipsychotic or fluoxetine or monoamine oxidase inhibitors (MAOIs) within 1 month, clozapine therapy within 3 months, long-acting risperidone within 100 d, or PP within 10 months prior to screening ; exposure to experimental treatment within 30 d of screening. Women were excluded if pregnant, nursing, or planning to become pregnant during the trial.
Prohibited concomitant medications included psychotropics (including over-the-counter and nutritional medications), anticonvulsants or mood stabilizers and MAOIs. Oral benztropine or biperiden (or equivalent agents) were permitted for the treatment of extrapyramidal system (EPS) symptoms, but all other anti-EPS therapies were prohibited. Lorazepam was permitted during the first week for agitation, anxiety, or sleep difficulties, but was tapered and discontinued by day 8. Antidepressants (excluding fluoxetine or MAOIs) were allowed if the dose was stable for at least 3 months before screening. Limited supportive psychotherapy and psychoeducational programmes were also permitted.
This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practice and applicable regulatory requirements. After receiving a complete description of the study, all patients signed a study informed consent document.
Study design, randomization, and blinding
C., funded this study, which was conducted in three phases over y11 wk. The study phases included : (1) screening (up to 5 d, including a 3-d washout of disallowed psychotropic medications) ; (2) a run-in phase (7 d) during which eligible patients were hospitalized and within each centre sequentially assigned one of four open-label once-daily morning doses of oral paliperidone [either of two formulations : paliperidone ER (6 mg, 12 mg) or paliperidone immediate release (2 mg, 4 mg)] ; and (3) a double-blind treatment phase (64 d) during which eligible patients were randomized 1 : 1 : 1 [via a sponsor-prepared computer-generated randomization and stratification scheme, with treatment assignment by an interactive voice-response system (IVRS)] to receive either PP 50 mg eq., PP 100 mg eq., or placebo, without oral supplementation. Patients were hospitalized for a minimum of 14 d, starting at the run-in phase, and could be discharged from the hospital after the second injection of study drug on day 8 if the investigator determined there was no significant risk of suicidal or violent behaviour and if the patient's Clinical Global Impression of Severity (CGI-S) score was 4 (moderately ill) or less.
A placebo arm was included to establish the ' true' (attributable) efficacy and safety profile of the study drug. A meta-analysis of successfully marketed antipsychotics (i.e. thought to be effective) from the Food and Drug Administration database showed that y25 % of studies failed to distinguish active medication from placebo (Laughren, 2001) . Observed placebo response rates in psychopharmacology studies vary from 20 % to 70 %. Additionally, the absence of evidence for excess risk of suicide in placebo-treated patients compared to drug-treated patients in schizophrenia trials argues for the acceptability of including a placebo arm (Laughren, 2001) .
Patients received a total of three separate injections, each injection administered intramuscularly in alternate gluteal muscles. The first two injections were administered 1 wk apart as single doses on day 1 and day 8 (together comprising the initial dosage regimen), followed 4 wk later by a single intramuscular injection on day 36. Doses of PP were selected to achieve a projected range of 70-80 % brain D 2 receptor occupancy (Karlsson et al. 2006) . Patients were hospitalized during the oral paliperidone run-in and during the first 7 d of the double-blind treatment phase. The oral run-in phase was designed to evaluate the safety and tolerability of switching from oral to injectable formulations of paliperidone in a typical clinical situation and to allow pharmacokinetic (PK) comparisons across the formulations.
Doses of PP can be expressed both in terms of milligram equivalents (mg eq.) of the pharmacologically active fraction, paliperidone, and in milligrams of PP. Thus, the doses expressed as ' PP 50 and 100 mg eq.,' equate to 78 and 156 mg, respectively, of PP.
Efficacy measures
The primary efficacy assessment was the mean change in PANSS total score (Kay et al. 1987 ) from baseline (day 1) to endpoint (day 64) during the double-blind phase for each PP dose and placebo. Secondary efficacy measures included : onset of effect (the first PANSS assessment at which there was a statistically significant difference in PANSS total score between active drug and placebo that was then maintained for the remainder of the study), treatment response (defined as at least 30 % improvement in PANSS total score from baseline to endpoint), and change from baseline to endpoint in the PANSS subscale scores (Lindenmayer et al. 1994 ; Marder et al. 1997 ) and CGI-S scores.
Safety and tolerability measures
Safety assessments included reports of treatmentemergent adverse events (TEAEs) (using the Medical Dictionary for Regulatory Activities, v. 8.0), clinical laboratory tests, vital sign measurements, body weight, physical examinations, 12-lead ECGs, movement disorder rating scales [Simpson Angus Scale (Simpson & Angus, 1970) , Barnes Akathisia Rating Scale (Barnes, 1989) , and Abnormal Involuntary Movement Scale (Guy, 1976) ] and serum prolactin values. Study personnel evaluated the injection site for induration, redness, pain, and swelling and the patient assessed the degree of pain at the injection site. QTc interval was corrected for heart rate using a linear-derived correction factor (QTcLD) (Sagie et al. 1992) .
PK assessments
Blood samples were taken for PK analysis on days x7, x1, 1, 8, 15, 18, 22, 29, 36, 43, 50, 57, and 64 . Plasma concentrations and PK parameters of patients enrolled at the six sites that did not appropriately use the IVRS were not included in the calculations for the descriptive analyses and graphical summaries.
On study days when the study drug was administered, the pre-dose PK blood sample was collected y10 min before study drug administration. The plasma concentrations of paliperidone were determined using a validated liquid chromatography coupled to a tandem mass spectrometry method, with a target limit of quantification of 0.2 ng/ml.
Statistical analyses
This study was designed to have 90 % power to detect a difference of at least 10 points on the change from baseline to endpoint in PANSS total score between placebo and either of the PP dose groups, with a significance level set at 0.10 (two-sided) and at least 70 patients per treatment group. A standard deviation of y20 was assumed. An a-level of 0.10 was chosen in consideration of the limited drug supply available at the time this phase 2 study was initiated. However, this a-level allowed selection of a sample size that was considered sufficient to meet the primary study objectives.
An analysis of covariance (ANCOVA) model with factors for treatment, analysis centre and oral runin treatment and with baseline PANSS total score as a covariate, was used to compare the change from baseline to endpoint for each active treatment group to placebo with no adjustments for multiplicity. Estimated least-square means of the difference between each PP group and placebo, with corresponding p values and 90 % confidence intervals, were produced for the change from baseline to endpoint in PANSS total score and factor scores. A similar ANCOVA model was used for a post-hoc analysis of percentage change in PANSS total score. The percentage change was calculated to take into account the minimum PANSS total score. For CGI-S, a similar ANCOVA model was used with ranked data. Responder-rate data were analysed using the Cochran-Mantel-Haenszel procedure, controlling for analysis centre. The last-observation-carried-forward (LOCF) approach was used for the primary analysis of the data. In addition, an analysis using the repeatedmeasures mixed-effects model was performed. Statistical analyses were performed using SAS version 9.1 (SAS Institute Inc., USA).
Descriptive statistics were provided to evaluate adverse events and changes from baseline in EPS rating scale scores, laboratory assessments, and vital signs. For ECG parameters and body weight an ANCOVA model with factors for treatment, analysis centre, and baseline value as a covariate was used to compare the change from baseline to endpoint for each active treatment group with placebo.
Populations assessed
All efficacy analyses from the double-blind phase used the intent-to-treat (ITT) analysis set, which included all randomized patients who received at least one dose of double-blind medication and had at least one valid post-baseline efficacy measurement. Patients from six sites (three in USA, three in India) did not receive double-blind medication according to the randomization schedule, as a result of incorrect use of IVRS. This error primarily resulted in omission of the second call, which was to provide additional dosing instructions for patients randomized to double-blind treatments. Although those patients who were assigned to placebo received the correct dosing, those assigned to PP did not and the actual dose received could not be confirmed. All patients from these six sites (n=49) were prospectively excluded from the primary ITT analysis. Evaluable patients from this group (n=46) were similarly divided among treatment groups and included in confirmatory analyses.
Safety summaries used data from all randomized patients who had taken at least one dose of study treatment and provided post-baseline safety data. This included patients from the six sites that did not follow correct randomization assignments.
Results
Patient population
A total of 266 patients met eligibility requirements for this study, which was conducted from October 2003 to July 2004 at 30 centres in the USA, Russia, Bulgaria, Poland, Ukraine, and India (see Appendix). Most (93 %) of the patients who entered the oral run-in period continued into the double-blind period. Of those who did not (n=19), four (2 %) withdrew due to adverse events (Fig. 1) . Of the 247 patients randomized, 125 (51 %) completed the 64-d double-blind period. Twice as many patients in the PP groups [50 mg eq. (n=47, 59 %) ; 100 mg eq. (n=51, 61 %)] completed the study compared to placebo-treated patients (n=27 [32 %]) (Fig. 1) .
A total of 197 (80 %) patients formed the ITT analysis set used for efficacy assessments, and 247 (100 %) contributed to the safety assessments. The ITT analysis set was predominately white (81 %) and male (62 %). The mean age was 39 yr (S.D.=10.3 yr). Most patients (88 %) were diagnosed with paranoid schizophrenia, 75 % of patients previously used antipsychotics in the 30 d before the study, and 67 % had three or more prior hospitalizations for psychosis. Baseline demographics, including psychiatric history, did not differ significantly among treatment groups in the ITT analysis set (Table 1) or between the ITT and safety analysis sets. Patients with at least a 15-point improvement in PANSS total score during the oral run-in phase were distributed similarly across double-blind phase treatment groups (Table 1) . In addition, the mean PANSS total scores at baseline were similar for each double-blind treatment group (Table 1) .
Dosing
Approximately 93 % (n=247) of the patients who entered the oral run-in phase continued into the doubleblind phase. In terms of drug exposure, 95 % (n=254) of patients in the oral run-in phase received oral paliperidone (as an extended-release or immediate-release formulation) for at least 7 d, at which time apparent steady state is achieved. Approximately 66 % (n=107) of PP-treated patients received all three injections, compared to 42 % (n=35) of placebo-treated patients.
Efficacy
Both doses of PP produced significant differences (pf0.001, Table 2) in the mean change in PANSS total score from baseline to endpoint (the primary measure), compared to placebo. Inclusion of patient data from the six excluded sites produced similar results. These differences were significant by day 8 for each palmitate group, compared to placebo, and were maintained to the end of the double-blind period (pf0.011) (Fig. 2) . Results of the mixed-effects model analysis were consistent with the primary analysis : both PP 50 and 100 mg eq. separated from placebo (pf0.002). PP treatment also resulted in significant improvement in the five PANSS factor scores and 30 % responder rates (Table 2) . A post-hoc analysis of percentage improvement in PANSS total scores also showed both PP 50 and 100 mg eq. separated from placebo (pf0.001) ( Study completion (day 64) (n=125) Fig. 1 . Study flow and patient disposition. Patients from six sites (n=49) were excluded from the ITT analyses, but are included here in patient accounting as they were part of the all randomized set. The strengths expressed as PP 50 and 100 mg eq. equate to 78 mg and 156 mg, respectively, of paliperidone palmitate.
showed symptom improvement at endpoint : 50 % of placebo-treated patients had a rating of marked, severe, or extremely severe, compared to 37 % for PP 50 mg eq. and 32 % for PP 100 mg eq. Both dose groups were statistically superior to placebo (pf0.004) in reducing CGI-S scores. (17) 4 (6) Olanzapine 6 (9) 6 (10) 6 (9) Trihexyphenidyl 9 (14) 3 (5) 5 (7) PP, Paliperidone palmitate ; BMI, Body mass index ; PANSS, Positive and Negative Syndrome Scale ; CGI-S, Clinical Global Impression of Severity scale. a The strength is expressed both in terms of milligram equivalents (mg eq.) of paliperidone, the pharmacologically active fraction, and in milligrams of PP. b One patient had a baseline score of 55, below the lower limit of 60 that was allowed per protocol. c n=65 for placebo ; n=62 for PP 50 mg eq. groups.
Safety evaluations
The overall incidence of TEAEs was similar in dose groups [safety analysis set (n=247) : 64 % for placebotreated patients, 65 % for PP 50 mg eq.-treated patients, and 60 % for PP 100 mg eq.-treated patients]. Discontinuation due to TEAEs occurred more frequently in the placebo group (10 %, n=8) compared to either PP group [50 mg eq. (3 %, n=2), 100 mg eq. (2 %, n=2)]. Psychiatric disorders (7 %, n=6), accounted for the majority of the discontinuations in the placebo group, with most of these classified as psychotic disorder (5 %, n=4). Insomnia, schizophrenia, and extrapyramidal disorder were the only TEAEs that occurred more frequently (i.e. o5 % difference) in any of the PP-treated groups than placebo (Fig. 3) . One patient receiving 4 mg paliperidone IR during the oral run-in phase reported akathisia 3 d before receiving double-blind phase medication (assigned to PP 50 mg eq.). Consequently, this adverse event was not classified as treatment-emergent in terms of PP. Of the four patients (2 %) in the combined PP group who discontinued due to TEAEs, three discontinued due to schizophrenia and one for pyelocystitis.
Parkinsonism-related adverse events (extrapyramidal disorder, drooling, and hypertonia) were the most common EPS-related adverse events and occurred more frequently in the PP groups [100 mg eq. (8 %, n=7), 50 mg eq. (5 %, n=4)] than placebo (1 %, n=1). All other EPS-related events occurred at similar, low rates across groups and none were severe in intensity. Movement disorder rating scales did not show any statistically significant or clinically relevant differences between the PP and placebo groups. However, the percentage of patients receiving anti-EPS medications was higher in the PP 100 mg eq. Paliperidone palmitate in schizophrenia 641 group (21 %, n=18)] than in the PP 50 mg eq. (10 %, n=8)] or placebo (7 %, n=6) groups. There were no reports of tardive dyskinesia. Serious TEAEs occurred in 19 patients during the double-blind phase ; six (7 %) received placebo and 13 (8 %) received PP. Psychotic disorder or schizophrenia (exacerbation of symptoms) was reported for most (n=15) of these patients : five patients treated with placebo, seven treated with PP 50 mg eq., and three treated with PP 100 mg eq. One case of elevated hepatic enzymes was reported in the placebo group. Additionally, in the PP groups, depression and suicidal ideation (n=1 ; 50 mg eq. group), psychomotor agitation (n=1 ; 100 mg eq. group), and syncope (n=1; 100 mg eq. group) were reported.
Median prolactin levels increased, more so in women than men, during the run-in phase, during which all patients were treated with oral paliperidone. Prolactin values decreased, relative to the increased baseline values, by endpoint of the double-blind treatment. However, the median values remained elevated for the PP treatment groups compared to median pre-dose treatment values (Table 3) . Prolactin levels decreased to pretreatment values for placebotreated patients. The incidence of potentially prolactin-related adverse events was low : one case of erectile disorder in a man (PP 50 mg eq.) and two cases of galactorrhoea in women (one in each of the PP 50 and 100 mg eq. groups). The woman treated with 50 mg eq. PP also reported amenorrhoea, as did one placebo-treated woman. There were no other clinically relevant treatment-related changes in any evaluated laboratory value, including lipids and glucose (Table 3) .
Treatment with PP was associated with significant mean increases in body weight and BMI from baseline to endpoint for both the 100 mg eq. group (pf0.001 both measures ; last observation available during the double-blind phase) and the 50 mg eq. group (p= 0.036 for BMI ; p=0.059 for weight ; last observation available during double-blind phase) compared to placebo (Table 3) . The percentage of patients with a >7 % increase in weight was low, with 6-8 % of patients in that category for the two PP dose groups vs. 4 % for placebo-treated patients. Weight increase was reported as a TEAE for three patients : one in the placebo group and two in the PP 50 mg eq. group.
Incidences of increased heart rate were higher for PP-treated patients than placebo, as were incidences of orthostatic hypotension (Table 3) . None of the incidences of orthostatic hypotension, defined by vital sign measurements, were reported as an adverse event. No case was symptomatic, except possibly for one PP 50 mg eq.-treated patient who reported nausea on the same day. There were no clinically relevant changes in QTcLD (i.e. o450 ms) reported for PPtreated patients and none had an increase in QTcLD 
Fig. 2. Change in PANSS total score over time (LOCF).
Mean change from baseline in PANSS total scores is shown, by treatment group, for each time-point assessed.
Intent-to-treat analysis set, which excludes patients from six sites. * pf0.011 (LOCF analysis) paliperidone palmitate (PP) group vs. placebo. Results for the repeated-measures mixed-effects model were consistent with the LOCF analysis : PP 50 mg eq. vs. placebo (p=0.0016) ; PP 100 mg eq. vs. placebo (p<0.0003). The strengths expressed as PP 50 and 100 mg eq. equate to 78 mg and 156 mg, respectively, of PP. Fig. 3 . Treatment-emergent adverse events occurring in at least 3 % of patients in any group. Paliperidone palmitate (PP) (50 mg eq.) overlaps placebo for extrapyramidal disorder rates ; PP 100 mg eq. overlaps placebo for myalgia and asthenia rates ; PP 100 mg eq. overlaps PP 50 mg eq. for hypertension rates. The strengths expressed as PP 50 and 100 mg eq. equate to 78 mg and 156 mg, respectively, of PP.
>60 ms at any time-point during the study. In general, pairwise comparisons of the mean changes from average pre-dose value between each PP group and placebo were not different for any of the ECG parameters measured in this study. Injection site tolerability was good overall. Throughout the study investigator-rated local injection-site pain was similar between PP and placebo treatment groups and generally absent or mild : absent (56-71 %), mild (24-39 %), moderate (2-12 %), or severe (0-2 %). Induration and swelling appeared in f10 % of patients in any group, but appeared to be more frequent in PP-treated patients. Redness was largely rated as absent or mild across groups. PP 100 mg eq. was associated with more redness for the first injection, but the incidence of redness was similar across PP groups for the subsequent two injections, although higher than placebo.
PK findings
For all treatments in the oral run-in period, apparent steady-state was achieved within 7 d after starting the oral run-in phase. In the 7-d period following the first intramuscular injection of PP, the median plasma concentrations of paliperidone gradually decreased from 18.9 ng/ml (pre-dose day 1) to 7.59 ng/ml (pre-dose day 8) for the PP 50 mg eq. group, and from 28.7 ng/ml (pre-dose day 1) to 8.24 ng/ml (pre-dose day 8) for the PP 100 mg eq. group. Following the third intramuscular injection of PP (on day 36), plasma concentrations of paliperidone slowly increased to reach a maximum about 4 d after each injection. Thereafter, plasma concentrations of paliperidone decreased gradually over 20-27 d (Fig. 4) .
Discussion
This phase 2b study was an initial study to assess the efficacy and safety of PP, an investigational atypical antipsychotic formulated as a long-acting injectable aqueous nanosuspension. Administered as an intramuscular injection into gluteal muscle (and not requiring oral supplementation), PP improved symptom control in this population of patients with schizophrenia. Mean change in PANSS total scores at endpoint, 4 wk after the last injection, demonstrated significant (pf0.001) reductions for both PP dose groups compared to placebo. At least 19 % more PPtreated patients achieved treatment response (i.e.
patients achieved at least a 30 % improvement in PANSS total score), compared to placebo, and the difference was significant for both PP dose groups. Both groups were also significantly different on the post-hoc analysis of percentage change in PANSS total scores. In addition, all secondary efficacy measures assessed, including CGI-S scores, showed significant changes vs. placebo, consistent with improvement in patients treated with PP. Onset of effect was early, with both doses showing statistical separation from placebo within 8 d of the first injection, and was maintained throughout the 2-month double-blind period. PP was generally tolerated systemically. The incidence of TEAEs was similar between PP-and placebotreated groups. The rate of discontinuations as a result of TEAEs was lower in patients treated with PP (2 %), compared to placebo (10 %). EPS-related adverse events were infrequent, and all were mild or moderate in severity. However, Parkinsonism-related adverse events did occur more frequently in the PP treatment groups (7 % overall) compared to placebo (1 %). More patients in the PP 100 mg eq. group used antiparkinson medication than patients in either the PP 50 mg eq. or placebo groups, which were similar in this respect. There were no reports of tardive dyskinesia.
Mean body weight increases, which were significant compared to placebo, were detected in both PP dose groups (y1 kg at endpoint). A 4-4.5 kg increase was reported over a 10-wk treatment period for olanzapine and clozapine (Allison et al. 1999) . Consistent with previously published information (Davidson et al. 2007 ; Kane et al. 2007 ; Marder et al. 2007) , prolactin levels increased during the oral run-in phase, in which all patients were treated with paliperidone ER. While they decreased for all groups during the double-blind phase, and decreased to normal for placebo-treated patients, mean prolactin levels remained above the upper limit of normal for PP-treated patients. The rates of potentially prolactin-related adverse events were low, consistent with other studies to date (Hough et al. in press ). However, it should be noted that assessing sexual dysfunction via spontaneous reports can result in underreporting.
There was no worsening noted in other metabolic parameters, including lipids and glucose.
Cardiovascular tolerability of PP administration appeared to be good overall, although the study was not powered to assess safety. No patient receiving PP experienced QTcLD prolongation or a QTcLD >450 ms during the study. PP treatment was associated with higher incidences of abnormally high heart rate (17 % combined PP vs. 8 % placebo) and orthostatic hypotension (9 % combined vs. 4 % placebo) as based on vital sign measurements. None of the incidences of orthostatic hypertension were reported as an adverse event and incidences of tachycardia as an adverse event were low (<2 %).
The aqueous nanosuspension formulation also resulted in good tolerability around the injection site. Investigators rated injection-site pain and redness predominately as absent or mild throughout the study. These are positive attributes for an injectable formulation of an atypical antipsychotic and similar to results seen for risperidone LAI, another aqueous-based injectable atypical antipsychotic (Lindenmayer et al. 2005) . Oil-based injectable formulations of conventional (typical) antipsychotics have been associated with injection-site pain and skin reactions (Hamann et al. 1990) . Furthermore, the severity of pain can affect patient attitudes towards treatment (Bloch et al. 2001) .
Because this was the first double-blind, placebocontrolled clinical study of PP, patient enrolment was limited to a modest sample size. In addition, this 9-wk study was relatively short and did not include an active comparator. Thus, conclusions regarding efficacy of PP compared to other antipsychotics, including oral paliperidone, should not be drawn. Finally, discontinuations rates were high in this study. However, it is worth noting that the LOCF and repeated-measures mixed-effects model analyses, which each handle drop-outs differently, yielded consistent results.
As with any clinical trial, the data are from a select patient population and results may not be fully generalizable. In fact, data from subsequent clinical and PK studies indicate that treatment initiation of PP using a 150 mg eq. dose in the deltoid muscle results in more consistent achievement of effective therapeutic levels across patients (Pandina et al. 2009 ; Samtani et al. 2009 ). Subsequent injections can be administered in either the gluteal or deltoid site (Hough et al. 2009 ).
This study included a 7-d oral run-in period that assessed the pharmacokinetics of two different formulations of paliperidone : an immediate release and an extended release (currently marketed). It is anticipated some clinicians may treat patients with an oral formulation for several days before initiation of PP. Treatment with the different oral formulations improved PANSS total scores during the run-in period. However, patients with an improvement in PANSS total scores during run-in were equally distributed across the three treatment groups and additionally, mean PANSS total scores were similar across treatment groups at double-blind baseline. A final consideration is that this study used the LOCF approach for the primary efficacy parameter.
Adherence issues with a daily oral regimen, frequently leading to repeated symptomatic relapses, continue to be a major problem in patients with schizophrenia taking oral antipsychotics (Byerly et al. 2005 ; Keith et al. 2004 ). Long-acting injectable antipsychotics may offer multiple advantages for patients with schizophrenia including improved assurance that patients have more continuous blood levels of an atypical antipsychotic. With the use of long-acting injectable formulations, missed injections can be easily detected and acted upon. There are very few options currently available among injectable formulations of atypical antipsychotics. PP demonstrated efficacy in quickly reducing the severity of symptoms and maintaining symptom control over a 2-month period. It was generally tolerated in this study.
